INVENTIVA: Inventiva reports its 2021 Full-Year Results: key

Initiation of the NATiV3 Phase III clinical trial with lanifibranor in NASH Receipt of a €4 m milestone payment from AbbVie following the inclusion of the first patient in the ongoing

Related Keywords

United States , Germany , New York , Daix , Bourgogne , France , Paris , France General , Netherlands , United Kingdom , Belgium , Russia , Switzerland , Ukraine , Brunswick , Niedersachsen , French , American , Nawal Ouzren , Pascaline Clerc , Martine Zimmerman , Aude Lepreux , Company American Depositary , Patricial Bank , Brunswick Group , Exchange Commission On , European Central Bank , Drug Administration , Health Care Conference , Nasdaq , Global External Affairs , International Conference On Fatty Liver , Long Island City , Euronext Paris , New England Journal , American Depositary Shares , Nasdaq Global Market , Public Offering , Securities Insurance , New Drug Application , Independent Director , Combined Shareholder Meeting , Patient First Visit , Annual Health Care Conference , Biomed Event , Annual Global Life Sciences Conference , Fatty Liver , Global External , Roquet Montegon , Private Securities Litigation Reform Act , Universal Registration Document , Des March , Annual Report , Exchange Commission , Inventiva , Reports , 021 , Bull , Ear , Results , Ilestones , Chieved , Anifibranor , Cash , Edirogant , Psoriasis ,